EP0926955A4 - Conjugates useful in the treatment of prostate cancer - Google Patents

Conjugates useful in the treatment of prostate cancer

Info

Publication number
EP0926955A4
EP0926955A4 EP97942423A EP97942423A EP0926955A4 EP 0926955 A4 EP0926955 A4 EP 0926955A4 EP 97942423 A EP97942423 A EP 97942423A EP 97942423 A EP97942423 A EP 97942423A EP 0926955 A4 EP0926955 A4 EP 0926955A4
Authority
EP
European Patent Office
Prior art keywords
treatment
prostate cancer
conjugates useful
conjugates
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97942423A
Other languages
German (de)
French (fr)
Other versions
EP0926955A1 (en
Inventor
Dong-Mei Feng
Victor M Garsky
Raymond E Jones
Allen I Oliff
Jenny M Wai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9624170.8A external-priority patent/GB9624170D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0926955A1 publication Critical patent/EP0926955A1/en
Publication of EP0926955A4 publication Critical patent/EP0926955A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
EP97942423A 1996-09-12 1997-09-10 Conjugates useful in the treatment of prostate cancer Withdrawn EP0926955A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2601596P 1996-09-12 1996-09-12
US26015P 1996-09-12
GBGB9624170.8A GB9624170D0 (en) 1996-11-19 1996-11-19 Conjugates useful in the treatment of prostate cancer
GB9624170 1996-11-19
PCT/US1997/016087 WO1998010651A1 (en) 1996-09-12 1997-09-10 Conjugates useful in the treatment of prostate cancer

Publications (2)

Publication Number Publication Date
EP0926955A1 EP0926955A1 (en) 1999-07-07
EP0926955A4 true EP0926955A4 (en) 2003-05-07

Family

ID=26310443

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97942423A Withdrawn EP0926955A4 (en) 1996-09-12 1997-09-10 Conjugates useful in the treatment of prostate cancer

Country Status (5)

Country Link
EP (1) EP0926955A4 (en)
JP (1) JP2001501601A (en)
AU (1) AU715632B2 (en)
CA (1) CA2265476A1 (en)
WO (1) WO1998010651A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999028345A1 (en) * 1997-12-02 1999-06-10 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6174858B1 (en) 1998-11-17 2001-01-16 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
DE69942128D1 (en) * 1998-12-11 2010-04-22 Coulter Pharm Inc PRODRUGS AND METHOD FOR THE PRODUCTION THEREOF
US6649587B1 (en) * 1999-04-30 2003-11-18 Slil Biomedical Corporation Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
US6552166B1 (en) * 1999-10-19 2003-04-22 Merck & Co., Inc. Process for the preparation of conjugates useful in the treatment of prostate cancer
GB9924759D0 (en) 1999-10-19 1999-12-22 Merck Sharp & Dohme Process for preparing peptide intermediates
EP1244693B1 (en) * 1999-12-06 2005-06-22 Hopital Sainte-Justine Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis
US6844318B2 (en) 2000-03-15 2005-01-18 Bristol Myers Squibb Pharma Company Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use
DE60231868D1 (en) * 2001-04-24 2009-05-20 Purdue Research Foundation FOLAT MIMETICS AND THEIR FOLAT RECEPTOR BINDING CONJUGATES
AU2003243226A1 (en) 2002-05-15 2003-12-02 Endocyte, Inc. Vitamin-mitomycin conjugates
EP2517730A3 (en) 2003-01-27 2013-01-02 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
CN100372862C (en) * 2003-11-05 2008-03-05 天津和美生物技术有限公司 Adriacin derivative with anti-cancer activity
JP5149620B2 (en) 2004-07-23 2013-02-20 エンドサイト，インコーポレイテッド Bivalent linker and conjugate thereof
JP5289935B2 (en) 2005-03-16 2013-09-11 エンドサイト，インコーポレイテッド Synthesis and purification of pteroic acid and its conjugates
EP1900742A1 (en) 2006-09-07 2008-03-19 AEterna Zentaris GmbH Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof
CN103948937A (en) 2007-03-14 2014-07-30 恩多塞特公司 Binding ligand linked drug delivery conjugates of tubulysins
RU2523909C2 (en) 2007-06-25 2014-07-27 Эндосайт, Инк. Conjugates, containing hydrophilic spacers of linkers
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
US9187521B2 (en) 2007-10-25 2015-11-17 Endocyte, Inc. Tubulysins and processes for preparing
CA2830349C (en) 2011-03-17 2019-07-16 The University Of Birmingham Re-directed immunotherapy
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
WO2014062697A2 (en) 2012-10-16 2014-04-24 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
GB201402267D0 (en) 2014-02-10 2014-03-26 Cambridge Entpr Ltd Antibacterial agents
EP3253419A1 (en) 2015-02-02 2017-12-13 The University of Birmingham Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes
ES2873846T3 (en) 2015-11-19 2021-11-04 Revitope Ltd Functional Antibody Fragment Complementation for a Two-Component System for Targeted Elimination of Unwanted Cells
CN116635054A (en) 2020-12-22 2023-08-22 科比欧尔斯公司 Compounds comprising tetrapeptide moieties
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0647450A1 (en) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
US5599686A (en) * 1994-06-28 1997-02-04 Merck & Co., Inc. Peptides
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
JP2000506494A (en) * 1995-10-18 2000-05-30 メルク エンド カンパニー インコーポレーテッド Complexes useful for treating benign prostatic hyperplasia

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *
See also references of WO9810651A1 *

Also Published As

Publication number Publication date
WO1998010651A1 (en) 1998-03-19
JP2001501601A (en) 2001-02-06
AU4412397A (en) 1998-04-02
CA2265476A1 (en) 1998-03-19
AU715632B2 (en) 2000-02-03
EP0926955A1 (en) 1999-07-07

Similar Documents

Publication Publication Date Title
EP0926955A4 (en) Conjugates useful in the treatment of prostate cancer
HK1024876A1 (en) Conjugates useful in the treatment of prostate cancer
AU1958897A (en) Egf-genistein conjugates for the treatment of cancer
IL189132A0 (en) Pharmaceutical compositions for the treatment of prostate hypertrophy and prostate cancer
IL136167A0 (en) Conjugates useful in the treatment of prostate cancer
EP0855910A4 (en) Conjugates useful in the treatment of benign prostatic hyperplasia
IL124650A0 (en) Methods and therapeutic compositions for treating cancer
ZA9810974B (en) Conjugates useful in the treatment of prostate cancer
EG22346A (en) Process for the preparation of conjugates useful in the treatment of prostate cancer
AU6111800A (en) 26 human prostate and prostate cancer associated proteins
GB9703633D0 (en) Cancer therapy
ZA979655B (en) Conjugates useful in the treatment of prostate cancer.
GB9626309D0 (en) Conjugates useful in the treatment of prostate cancer
GB9624170D0 (en) Conjugates useful in the treatment of prostate cancer
SI0942754T1 (en) Conjugates useful in the treatment of prostate cancer
GB9718160D0 (en) Conjugates useful in the treatment of prostate cancer
GB9804399D0 (en) Conjugates useful in the treatment of prostate cancer
GB9815855D0 (en) Conjugates useful in the treatment of prostate cancer
GB9810183D0 (en) Conjugates useful in the treatment of prostate cancer
GB9804361D0 (en) Cancer treatment
HK1034979A1 (en) Conjugates useful in the treatment of prostate cancer.
EP0871709A4 (en) Androgen-repressed metastatic human prostate cancer cell line
GB9903035D0 (en) Treating cancer
GB2334579B (en) Treating cancer
GB9617941D0 (en) New approach to the treatment of prostate cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990412

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20030320

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 38/16 B

Ipc: 7A 61K 38/28 B

Ipc: 7A 61K 38/00 B

Ipc: 7A 01N 37/18 B

Ipc: 7A 61K 47/48 A

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20040121